A Pilot Study of the Use of 129Xe and 1H MRI to Measure the Modulation of Eosinophil-Related Inflammation by Mepolizumab In COPD

NCT05138250 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

31

Enrollment

OTHER

Sponsor class

Conditions

COPD

Interventions

DRUG: Mepolizumab 100 MG

Sponsor

Sheffield Teaching Hospitals NHS Foundation Trust

Collaborators

[object Object]